<DOC>
	<DOCNO>NCT01205529</DOCNO>
	<brief_summary>The purpose study look similarity people 's gene may help understand people could benefit certain drug treatment atrial fibrillation .</brief_summary>
	<brief_title>Certain People With Atrial Fibrillation May Have Changes Ecg When Given Procainamide That May Related Genetic Difference</brief_title>
	<detailed_description>Current drug therapy suppress AF incompletely unpredictably effective carry significant ( albeit generally small ) risk serious adverse effect , include drug-induced long QT syndrome ( diLQTS ) , form proarrhythmia , increased mortality uncertain mechanism , extracardiac toxicity . Identification clinical genetic subtypes AF permit stratification therapeutic approach thereby facilitate practice personalize medicine . Furthermore , limited success drug therapy increase drug toxicity AF probably arrhythmia represent final common pathway multiple initiating mechanism , include genetically-defined . Identifying specific intermediate phenotype ( `` endophenotypes '' ) associate defined clinical course AF represent potential method systematically subtype patient underlie mechanism represent much-needed clinical advance . Clinical endophenotypes study include atrial fibrillatory rate , prolong signal-averaged P-wave duration , biomarker profile . The endophenotype study right precordial ST segment elevation , see Brugada syndrome ( BrS ) ( unmasked sodium channel block drug ) also commonly lone AF patient AF-associated rare variant gene encode cardiac sodium channel α- β-subunits . Taken together data suggest hypothesis test study , variant multiple gene culminate similar AF-prone substrate reduce sodium current identify screening baseline manifest right precordial ST segment elevation endophenotype sodium channel block intravenous procainamide .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Procainamide</mesh_term>
	<criteria>18 year age old Undergoing AF ablation Vanderbilt MGH Patients take membrane active antiarrhythmic drug sodium channel block property ( amiodarone , dronedarone , flecainide , propafenone ) time ablation Patients history Brugada syndrome type 1 Brugada ECG pattern baseline ECG Patients history druginduced torsades de pointes Patients know history hypersensitivity procainamide , procaine relate drug Patients history systemic lupus erythematosus myasthenia gravis Patients history second degree AV block ( Mobitz type II ) third degree AV block Women childbearing potential unless postmenopausal , surgically sterile , negative pregnancy test day day procedure Patients dual chamber pacemaker implantable defibrillator require ventricular pacing ( uninterpretable ECG ) Patients unable give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Atrial Fibrillation</keyword>
	<keyword>ST elevation</keyword>
	<keyword>Genotype</keyword>
</DOC>